Method and kit for reducing the symptoms of peripheral vascular disease

• US 7,572,780 B2
• Filed: 01/21/2003
• Issued: 08/11/2009
• Est. Priority Date: 01/21/2003
• Status: Expired due to Fees

• Current Assignee: Dimera Incorporated
• Original Assignee: Dimera Incorporated
• Inventors: Hermsmeyer, R. Kent
• Primary Examiner(s): Wang; Shengjun
• Application Number:
  US10/348,570
• Publication Number:
  US 20040142913A1
• Time in Patent Office: 2,394 Days
• Field of Search: 514/177, 514/178
• US Class Current: 514/177
• CPC Class Codes: A61K 31/57 substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 21/00 Drugs for disorders of the muscular or neuromuscular system
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 37/02 Immunomodulators
• CPC Class Codes: A61P 7/02 Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/08 Vasodilators for multiple indications
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

A method for reducing the symptoms of peripheral vascular disease wherein a chemical agent that reduces peripheral vascular hyperreactivity in response to a stimulus for contraction of peripheral vascular musculature is administered to a subject in need thereof. Kits for administering the chemical agent to reduce the symptoms of peripheral vascular disease.

Claims

1. A method for reducing the symptoms of peripheral vascular disease (PVD) comprising administering to a subject in need thereof a progestin in an amount that is effective to reduce the incidence and/or severity of symptoms of PVD, thereby reducing the incidence and/or the severity of symptoms of PVD, wherein the progestin is administered by topical application to the skin in a composition in which progestin is the sole chemical agent that is effective in reducing the incidence and/or severity of symptoms of PVD.

2. The method of claim 1 wherein the PVD is selected from the group consisting of Raynaud'"'"'s, intermittent claudication, thromboangiitis obliterans, and PVD secondary to diabetes, lupus, scleroderma, or atherosclerosis.

3. The method of claim 1 wherein the PVD is Raynaud'"'"'s.

4. The method of claim 1 wherein the progestin is progesterone.

5. The method of claim 1 wherein the administration is oral.

6. The method of claim 1 wherein the topical application is by a cream, lotion, gel, or ointment.

7. The method of claim 1 wherein the topical administration is by a transdermal patch.

8. The method of claim 1 wherein the progestin is progesterone.

9. A method to decrease peripheral vascular muscle hyperreactivity comprising administering to a subject in need thereof a progestin in an amount that is effective to decrease peripheral vascular hyperreactivity, wherein the progestin is administered by topical application to the skin in a composition in which progestin is the sole chemical agent that is effective to decrease peripheral vascular hyperreactivity.

10. The method of claim 9 wherein the progestin is progesterone.

11. The method of claim 9 wherein the topical application is by a cream, lotion, gel, or ointment.

12. The method of claim 9 wherein the topical administration is by a transdermal patch.

13. The method of claim 9 wherein the progestin is progesterone.

14. A method to improve peripheral circulation by reducing vascular muscle hyperreactivity comprising administering to a subject in need thereof a progestin in an amount that is effective to improve peripheral circulation by reducing vascular muscle hyperreactivity, wherein the progestin is administered by topical application to the skin in a composition in which progestin is the sole chemical agent that is effective to improve peripheral circulation by reducing vascular muscle hyperreactivity.

15. The method of claim 14 wherein the subject is suffering from a peripheral vascular disease (PVD).

16. The method of claim 15 wherein the PVD is selected from the group consisting of Raynaud'"'"'s, intermittent claudication, thromboangiitis obliterans, and PVD secondary to diabetes, lupus. sclerodermia, or atherosclerosis.

17. The method of claim 16 wherein the PVD is Raynaud'"'"'s.

18. The method of claim 14 wherein the progestin is progesterone.

19. The method of claim 14 wherein the topical application is by a cream, lotion, gel, or ointment.

21. The method of claim 14 wherein the progestin is progesterone.

20. The method of 14 wherein the topical administration is by a transdermal patch.